Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Identifieur interne : 000749 ( PubMed/Corpus ); précédent : 000748; suivant : 000750Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Auteurs : Kenneth Marek ; John Seibyl ; Shirley Eberly ; David Oakes ; Ira Shoulson ; Anthony E. Lang ; Chris Hyson ; Danna JenningsSource :
- Neurology [ 1526-632X ] ; 2014.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Brain (diagnostic imaging), Brain (metabolism), Dopamine Plasma Membrane Transport Proteins (metabolism), Female, Follow-Up Studies, Humans, Levodopa (therapeutic use), Longitudinal Studies, Male, Middle Aged, Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Radionuclide Imaging, Randomized Controlled Trials as Topic.
- MESH :
- chemical , metabolism : Dopamine Plasma Membrane Transport Proteins.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnostic imaging : Brain, Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Parkinson Disease.
- Adult, Aged, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Radionuclide Imaging, Randomized Controlled Trials as Topic.
Abstract
To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up.
DOI: 10.1212/WNL.0000000000000424
PubMed: 24759846
Links to Exploration step
pubmed:24759846Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.</title><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada. kmarek@indd.org.</nlm:affiliation></affiliation></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Hyson, Chris" sort="Hyson, Chris" uniqKey="Hyson C" first="Chris" last="Hyson">Chris Hyson</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24759846</idno><idno type="pmid">24759846</idno><idno type="doi">10.1212/WNL.0000000000000424</idno><idno type="wicri:Area/PubMed/Corpus">000749</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000749</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.</title><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada. kmarek@indd.org.</nlm:affiliation></affiliation></author><author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Hyson, Chris" sort="Hyson, Chris" uniqKey="Hyson C" first="Chris" last="Hyson">Chris Hyson</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name><affiliation><nlm:affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Neurology</title><idno type="eISSN">1526-632X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Brain (diagnostic imaging)</term><term>Brain (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins (metabolism)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Radionuclide Imaging</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Radionuclide Imaging</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24759846</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>20</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.</ArticleTitle><Pagination><MedlinePgn>1791-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000424</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Baseline (n = 799) and 22-month follow-up (n = 701) [(123)I] β-CIT SPECT scans were acquired. The percent change in [(123)I] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [(123)I] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.</AbstractText><CopyrightInformation>© 2014 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marek</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada. kmarek@indd.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seibyl</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberly</LastName><ForeName>Shirley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyson</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Danna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Parkinson Study Group PRECEPT Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neuroimaging. 1999 Oct;9(4):223-8</RefSource><PMID Version="1">10540602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1223-8</RefSource><PMID Version="1">20547625</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2000 Jun;47(6):804-8</RefSource><PMID Version="1">10852547</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Nov 28;55(10):1540-7</RefSource><PMID Version="1">11094111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2001 Feb;39(2):101-8</RefSource><PMID Version="1">11180497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Dec 11;57(11):2089-94</RefSource><PMID Version="1">11739831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Nov;16(6):1023-32</RefSource><PMID Version="1">11748733</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):36-43</RefSource><PMID Version="1">11790633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2002 Apr 3;287(13):1653-61</RefSource><PMID Version="1">11926889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2002 Oct;59(10):1541-50</RefSource><PMID Version="1">12374491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2002 Dec;59(12):1937-43</RefSource><PMID Version="1">12470183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2003 Jul;54(1):93-101</RefSource><PMID Version="1">12838524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Dec;18(12):1415-23</RefSource><PMID Version="1">14673877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Aug;61(8):1224-9</RefSource><PMID Version="1">15313838</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1995 Oct;38(4):589-98</RefSource><PMID Version="1">7574455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1996 Apr;119 ( Pt 2):585-91</RefSource><PMID Version="1">8800950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2498-508</RefSource><PMID Version="1">15590952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Mar 14;66(5):664-71</RefSource><PMID Version="1">16481597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1229-38</RefSource><PMID Version="1">17486648</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Oct 9;69(15):1480-90</RefSource><PMID Version="1">17881719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Nov 15;22(15):2210-5</RefSource><PMID Version="1">17712858</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Aug;10(8):432-3</RefSource><PMID Version="1">25002108</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4035714</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24759846</ArticleId><ArticleId IdType="pii">WNL.0000000000000424</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000424</ArticleId><ArticleId IdType="pmc">PMC4035714</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000749 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000749 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24759846
|texte= Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24759846" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |